Zoletrust Injection 4 mg/5 ml contains Zoledronic Acid 4 mg per 5 ml, a potent bisphosphonate used primarily for the treatment of hypercalcemia of malignancy (HCM) and bone-related complications in cancer patients. Hypercalcemia, an elevated level of calcium in the blood, often occurs in patients with cancer, especially those with bone metastases, and can lead to severe complications such as kidney failure, confusion, fatigue, and cardiac arrhythmias.

Zoletrust works by inhibiting bone resorption, thereby lowering elevated calcium levels and restoring normal mineral balance. Its intravenous formulation allows rapid and controlled correction of hypercalcemia, making it an essential therapy for acute management of life-threatening conditions.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Zoledronic Acid 4 mg per 5 ml injection

Mechanism of Action

Zoledronic Acid in Zoletrust Injection functions as follows:

1. Inhibits osteoclast-mediated bone resorption – Zoledronic acid binds to hydroxyapatite in bone, preventing osteoclasts from breaking down bone tissue.

2. Reduces calcium release into the bloodstream – By suppressing bone resorption, it lowers serum calcium levels.

3. Induces osteoclast apoptosis – Leads to long-term reduction of excessive bone breakdown.

4. Rapid and potent action – Provides fast normalization of calcium levels in patients with hypercalcemia of malignancy.

5. Prolonged effect – Maintains calcium levels for weeks, reducing the need for frequent interventions.

This mechanism makes Zoletrust highly effective in managing hypercalcemia and protecting skeletal health in cancer patients.

Indications

Zoletrust Injection 4 mg/5 ml is indicated for:

• Hypercalcemia of malignancy (HCM) – Rapid correction of elevated serum calcium in cancer patients

• Bone metastases in cancer – Reduces skeletal-related complications such as fractures or pain

• Osteolytic lesions – Common in multiple myeloma or metastatic breast cancer

• Prevention of recurrent hypercalcemia – In patients at high risk due to bone involvement

• Other clinical scenarios – As determined by a qualified healthcare professional

Dosage and Administration

• Adults: Standard dose is 4 mg IV infusion over at least 15 minutes; the exact regimen may vary depending on renal function and severity of hypercalcemia.

• Frequency: Usually administered once, with repeated dosing considered based on clinical response and calcium levels.

• Preparation: Dilute the injection in 100 ml of 0.9% sodium chloride for intravenous infusion; avoid rapid bolus injection to reduce risk of adverse events.

• Monitoring: Regular serum calcium, renal function, electrolytes, and hydration status should be assessed before and after infusion.

Benefits

• Rapidly reduces elevated calcium levels in hypercalcemia of malignancy

• Prevents skeletal-related complications in cancer patients

• Long-lasting effect, reducing the need for frequent interventions

• Easy intravenous administration suitable for hospital and outpatient use

• Improves quality of life in patients with bone metastases or multiple myeloma

Precautions

• Use with caution in renal impairment; dose adjustment may be necessary

• Ensure adequate hydration before infusion to minimize kidney toxicity

• Monitor for electrolyte disturbances such as hypocalcemia, hypophosphatemia, and hypomagnesemia

• Pregnancy and breastfeeding: Use only if clearly indicated

• Avoid co-administration with other nephrotoxic drugs if possible

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects:

• Fever, fatigue, or flu-like symptoms

• Nausea, vomiting, or constipation

• Mild hypocalcemia or hypophosphatemia

• Injection site reactions

Serious side effects:

• Renal impairment or acute kidney injury

• Severe hypocalcemia causing tetany, muscle cramps, or arrhythmias

• Osteonecrosis of the jaw (rare, usually in long-term use)

• Allergic reactions including rash or hypotension

Seek immediate medical attention if severe symptoms or kidney-related complications occur.

Storage

• Store 2–8°C (refrigerated) in a dry place

• Protect from light

• Keep vials in original packaging until use

• Keep out of reach of children

Zoletrust Injection 4 mg/5 ml provides rapid, effective management of hypercalcemia of malignancy, improving calcium balance, preventing skeletal complications, and supporting the overall care of cancer patients with bone involvement.